Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by NEOS Investment Management LLC

NEOS Investment Management LLC cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,503 shares of the biotechnology company’s stock after selling 3,990 shares during the quarter. NEOS Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,156,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,000. Van ECK Associates Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV increased its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $149,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $190,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the transaction, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the sale, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. This trade represents a 0.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 286,317 shares of company stock worth $5,049,735 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $13.82 on Friday. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market capitalization of $1.90 billion, a P/E ratio of -2.67 and a beta of 0.92. The firm has a 50-day moving average price of $18.13 and a two-hundred day moving average price of $19.61. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $13.66 and a twelve month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reaffirmed a “buy” rating and issued a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and an average target price of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.